Etiology, Pathophysiology, and Treatment of Atrial Fibrillation Part 1

被引:18
|
作者
Arortow, Wilbert S. [1 ]
机构
[1] New York Med Coll, Westchester Med Ctr, Div Cardiol, Dept Med, Valhalla, NY 10595 USA
关键词
atrial fibrillation; beta blockers; stroke; cardiovascular disease; cardioversion; digoxin; calcium channel blockers; radiofrequency catheter ablation; pacemakers; antiarrhythmic drugs;
D O I
10.1097/CRD.0b013e31816de1e3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Atrial fibrillation (AF) is associated with a higher incidence of mortality, stroke, and coronary events than is sinus rhythm. AF with a rapid ventricular rate may cause a tachycardia-related cardiomyopathy. Immediate direct-current cardioversion should be performed in patients with AF and acute myocardial infarction, chest pain due to myocardial ischemia, hypotension, severe heart failure, or syncope. Intravenous beta blockers, verapamil, or diltiazem may be given to immediately slow a very rapid ventricular rate in AF. An oral beta blocker, verapamil, or diltiazem should be used in persons with AF if a fast ventricular rate occurs at rest or during exercise despite digoxin. Amiodarone may be used in selected patients with symptomatic life-threatening AF refractory to other drugs. Digoxin should not be used to treat patients with paroxysmal AF. Nonpharmacologic therapies should be used in patients with symptomatic AF in whom a rapid ventricular rate cannot be slowed by drugs. This is part 1 of a 2-part review of the etiology, pathophysiology, and treatment of atrial fibrillation. The second part will be published in the subsequent issue of Cardiology in Review.
引用
收藏
页码:181 / 188
页数:8
相关论文
共 50 条
  • [1] Atrial fibrillation in horses part 1: Pathophysiology
    Decloedt, Annelies
    Van Steenkiste, Glenn
    Vera, Lisse
    Buhl, Rikke
    van Loon, Gunther
    VETERINARY JOURNAL, 2020, 263
  • [2] Atrial Fibrillation (Part 1): Pathophysiology, Risk Factors, and Therapeutic Basis
    Cintra, Fatima Dumas
    de Oliveira Figueiredo, Marcio Jansen
    ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2021, 116 (01) : 129 - 139
  • [3] ABC OF ATRIAL-FIBRILLATION - ETIOLOGY, PATHOPHYSIOLOGY, AND CLINICAL-FEATURES
    LIP, GYH
    BEEVERS, DG
    SINGH, SP
    WATSON, RDS
    BRITISH MEDICAL JOURNAL, 1995, 311 (7017): : 1425 - 1428
  • [4] Atrial fibrillation (part 1)
    Perrenoud, J. -J.
    EUROPEAN GERIATRIC MEDICINE, 2011, 2 (01) : 26 - 30
  • [5] Atrial fibrillation: Pathophysiology
    Schoels, W
    Bauer, A
    Becker, R
    Senges, JC
    Voss, F
    HERZ, 2002, 27 (04) : 306 - 311
  • [6] Pathophysiology and Treatment Modalities for Atrial Fibrillation: Present and Future
    Prasad, Kailash
    Elefteriades, John A.
    INTERNATIONAL JOURNAL OF ANGIOLOGY, 2020, 29 (02) : 63 - 64
  • [7] An update on atrial fibrillation in 2014: From pathophysiology to treatment
    Ferrari, R.
    Bertini, M.
    Blomstrom-Lundqvist, C.
    Dobrev, D.
    Kirchhof, P.
    Pappone, C.
    Ravens, U.
    Tamargo, J.
    Tavazzi, L.
    Vicedomini, G. G.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 203 : 22 - 29
  • [8] Atrial fibrillation: classification, pathophysiology, mechanisms and drug treatment
    Markides, V
    Schilling, RJ
    HEART, 2003, 89 (08) : 939 - 943
  • [9] Pathophysiology of Idiopathic Atrial Fibrillation - Prognostic and Treatment Implications
    Weijs, B.
    Schotten, U.
    Crijns, H. J. G. M.
    CURRENT PHARMACEUTICAL DESIGN, 2015, 21 (05) : 551 - 572
  • [10] Atrial fibrillation - Links between principles of pathophysiology and treatment
    Laszlo, R.
    Graze, H.
    Laszlo, S.
    Schreieck, J.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2010, 135 (17) : 862 - 867